1
|
Medina Villaamil V, Vazquez-Estevez S, Campos B, Leon Mateos L, Fírvida JL, Ramos M, Afonso FJ, Fernández Calvo O, Valladares Ayerbes M, Antón Aparicio LM. GAPDH, YWHAZ, and RRN18S as control reference genes for gene expression studies on renal cell carcinoma (RCC) formaldehyde-fixed paraffin-embedded (FFPE) tissue samples. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.389] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
389 Background: It is mandatory to have a control reference gen (RG) to correctly measure gene expression by real-time quantitative PCR (qPCR). The purpose of this study was to test a panel of 12 RGs (Human Endogenous Control Gene Panel, tataabiocenter) in order to select and validate the most appropriate control genes for expression studies on FFPE RCC tissues. Methods: qPCR followed by Normfinder and geNorm-based analysis was employed (GenEx Standard). The study was performed on 9 selected RCC tumor samples with different local stage (T1, T2 and T3). The most representative RCC histologies were also collected; clear-cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC) and cromophobe renal cell carcinoma (cRCC). A commercial pool (Biochain) of 5 cases of normal kidney was analyzed too. All samples were measured in triplicate. Expression levels of RGs: GAPDH, TUBB, PPIA, ACTB, YWHAZ, RRN18S, B2M, UBC, TBP, RPLP, GUSB and HPRT1 were measured by qPCR on a Light Cycler 480 (Roche) utilizing Light Cycler 480 SYBR Green I Master (Roche). Results: The analysis of experimental data showed that RRN18S is the most stable gene found in our FFEP RCC samples followed by GUSB and TBP. In contrast, ACTB was found to be the least stable gene between our samples. GAPDH together with YWHAZ was showed as the pair of genes introducing the least systematic error into data normalization (M-value < 1) needed to conduct expression gene studies further. Conclusions: These data suggest that GAPDH, YWHAZ and RRN18S are the most suitable RGs for gene expression profile studies in FFEP RCC. Standardization of RGs will help us to compare results from translational studies on RCC FFPE samples genes profiling. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- V. Medina Villaamil
- Instituto de Investigación Biomédica de A Coruñna, A Coruñna, Spain; Complexo Xeral-Calde, Lugo, Spain; Hospital Xeral-Calde, Lugo, Spain; Oncology Service, Complejo Hospitalario Universitario de Santiago, Santiago, Spain; Complexo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complexo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, Spain; Oncology Service, Complexo Hospitalario de Ourense, Ourense, Spain; Oncology Service, Complejo Hospitalario
| | - S. Vazquez-Estevez
- Instituto de Investigación Biomédica de A Coruñna, A Coruñna, Spain; Complexo Xeral-Calde, Lugo, Spain; Hospital Xeral-Calde, Lugo, Spain; Oncology Service, Complejo Hospitalario Universitario de Santiago, Santiago, Spain; Complexo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complexo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, Spain; Oncology Service, Complexo Hospitalario de Ourense, Ourense, Spain; Oncology Service, Complejo Hospitalario
| | - B. Campos
- Instituto de Investigación Biomédica de A Coruñna, A Coruñna, Spain; Complexo Xeral-Calde, Lugo, Spain; Hospital Xeral-Calde, Lugo, Spain; Oncology Service, Complejo Hospitalario Universitario de Santiago, Santiago, Spain; Complexo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complexo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, Spain; Oncology Service, Complexo Hospitalario de Ourense, Ourense, Spain; Oncology Service, Complejo Hospitalario
| | - L. Leon Mateos
- Instituto de Investigación Biomédica de A Coruñna, A Coruñna, Spain; Complexo Xeral-Calde, Lugo, Spain; Hospital Xeral-Calde, Lugo, Spain; Oncology Service, Complejo Hospitalario Universitario de Santiago, Santiago, Spain; Complexo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complexo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, Spain; Oncology Service, Complexo Hospitalario de Ourense, Ourense, Spain; Oncology Service, Complejo Hospitalario
| | - J. L. Fírvida
- Instituto de Investigación Biomédica de A Coruñna, A Coruñna, Spain; Complexo Xeral-Calde, Lugo, Spain; Hospital Xeral-Calde, Lugo, Spain; Oncology Service, Complejo Hospitalario Universitario de Santiago, Santiago, Spain; Complexo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complexo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, Spain; Oncology Service, Complexo Hospitalario de Ourense, Ourense, Spain; Oncology Service, Complejo Hospitalario
| | - M. Ramos
- Instituto de Investigación Biomédica de A Coruñna, A Coruñna, Spain; Complexo Xeral-Calde, Lugo, Spain; Hospital Xeral-Calde, Lugo, Spain; Oncology Service, Complejo Hospitalario Universitario de Santiago, Santiago, Spain; Complexo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complexo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, Spain; Oncology Service, Complexo Hospitalario de Ourense, Ourense, Spain; Oncology Service, Complejo Hospitalario
| | - F. J. Afonso
- Instituto de Investigación Biomédica de A Coruñna, A Coruñna, Spain; Complexo Xeral-Calde, Lugo, Spain; Hospital Xeral-Calde, Lugo, Spain; Oncology Service, Complejo Hospitalario Universitario de Santiago, Santiago, Spain; Complexo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complexo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, Spain; Oncology Service, Complexo Hospitalario de Ourense, Ourense, Spain; Oncology Service, Complejo Hospitalario
| | - O. Fernández Calvo
- Instituto de Investigación Biomédica de A Coruñna, A Coruñna, Spain; Complexo Xeral-Calde, Lugo, Spain; Hospital Xeral-Calde, Lugo, Spain; Oncology Service, Complejo Hospitalario Universitario de Santiago, Santiago, Spain; Complexo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complexo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, Spain; Oncology Service, Complexo Hospitalario de Ourense, Ourense, Spain; Oncology Service, Complejo Hospitalario
| | - M. Valladares Ayerbes
- Instituto de Investigación Biomédica de A Coruñna, A Coruñna, Spain; Complexo Xeral-Calde, Lugo, Spain; Hospital Xeral-Calde, Lugo, Spain; Oncology Service, Complejo Hospitalario Universitario de Santiago, Santiago, Spain; Complexo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complexo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, Spain; Oncology Service, Complexo Hospitalario de Ourense, Ourense, Spain; Oncology Service, Complejo Hospitalario
| | - L. M. Antón Aparicio
- Instituto de Investigación Biomédica de A Coruñna, A Coruñna, Spain; Complexo Xeral-Calde, Lugo, Spain; Hospital Xeral-Calde, Lugo, Spain; Oncology Service, Complejo Hospitalario Universitario de Santiago, Santiago, Spain; Complexo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complexo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, Spain; Oncology Service, Complexo Hospitalario de Ourense, Ourense, Spain; Oncology Service, Complejo Hospitalario
| |
Collapse
|
2
|
Casal J, Varela S, Anido U, Lázaro M, Fírvida JL, Vazquez-Estevez S, Villanueva M, Amenedo M, Caeiro M, Gomez A. Docetaxel (D) and cisplatin (C) induction chemotherapy followed by concurrent thoracic radiotherapy (TRT) and biweekly D and C for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Leon L, Vazquez S, Gracia J, Casal J, Lázaro M, Fírvida JL, Amenedo M, Santomé L, Cardona JV, Maciá S. A Galician Lung Cancer Group phase II study of bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Leon L, Vázquez S, Gracia JM, Lázaro M, Fírvida JL, Casal J, Amenedo M, Santomé L, Gallego R, Anido U. Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19089 Background: Bevacizumab, an anti-VEGF monoclonal antibody, improves response rates and prolongs survival in p with non squamous NSCLC when combined with carboplatin-paclitaxel or cisplatin-gemcitabine. This single-arm, open-labeled phase II trial aims to evaluate the efficacy and safety profile of B in combination with another widely used chemotherapy doublet for NSCLC: cisplatin and vinorelbine. Methods: Chemotherapy-naïve p diagnosed with stage IIIB or IV non squamous NSCLC received cisplatin (80 mg/m2), vinorelbine (25 mg/m2 IV days 1 and 8) and B (15 mg/kg IV) on day 1 every 3 weeks for up to 6 cycles followed by B 15 mg/kg alone every 3 weeks until disease progression. Main eligibility criteria were: PS 0–1, no brain metastases, no history of hemoptysis, stable cardiac condition and no full dose anticoagulation. Primary endpoint was progression-free survival and secondary endpoints were RR, duration of response, OS, 1-year survival and safety profile of the combination. Results: 38 p have been enrolled in the study and data of 27 p have been included in this analysis. P characteristics were: male 66.7%; median age 57 years (range 41–74); ECOG PS 0/1 (%) 33.3/66.7; adenocarcinoma/other (%) 74.1/25.9; stage IIIB/IV (%) 25.9/74.1. Median number of cycles for B/cisplatin/vinorelbine was 4.0 (range 1–6) and median number of cycles for B maintenance was 2 (range 1–4). 17 p were evaluable for response according to RECIST criteria: PR 29.4% and SD 41.2%. With a median follow-up of 3.9 months (range 0.7–11.1), median PFS was 4.6 months (95% CI: 2.6–6.6) and median OS has not been reached yet. Hematological toxicities were: 1 p gr. 3 anemia; 2 p gr. 3 and 2 p gr. 4 leucopenia; 10 p gr. 3, 1 p gr. 4 neutropenia and 3 p febrile neutropenia. Most common grade 3/4 non hematological toxicities were: vomiting (1p gr. 4), high blood pressure, asthenia and hyperglycemia. 1 p experienced gr. 4 abdominal pain, 1 p. gr. 4 constipation, 1 p. gr. 4 nausea and 1 p gr. 4 respiratory infection. No grade 3/4 hemoptysis were reported. Conclusions: This interim analysis shows that B in combination with cisplatin and vinorelbine is safe and well tolerated and has a promising activity in chemo-naïve p with non squamous NSCLC. Survival data will be updated. [Table: see text]
Collapse
Affiliation(s)
- L. Leon
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - S. Vázquez
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. M. Gracia
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - M. Lázaro
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. L. Fírvida
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. Casal
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - M. Amenedo
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - L. Santomé
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - R. Gallego
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - U. Anido
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| |
Collapse
|
5
|
Casal J, Vázquez S, León L, Lázaro M, Fírvida JL, Amenedo M, Alonso G, Santomé L, Afonso FJ. Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7537] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7537 Background: Combination of platinum-based chemotherapy and radiotherapy is the standard treatment for p with unresectable stage III NSCLC, but considering the high rates of recurrence, it is necessary to improve these results. Erlotinib is an EGFR TKI that prolongs survival in p with recurrent and metastatic NSCLC. In this study, we aim to evaluate the role of erlotinib as maintenance therapy after a standard concurrent chemo-radiotherapy regimen in p with stage III NSCLC. Methods: P with unresectable stage IIIA/IIIB—without malignant effusions—NSCLC who had received a standard concurrent chemo-radiotherapy regimen and had no evidence of tumor progression were enrolled in this single arm, open-label phase II study and received erlotinib 150 mg/day po for 6 months. Main eligibility criteria were: PS 0–2, adequate bone marrow, hepatic and renal function and measurable disease by RECIST criteria. Primary endpoint was the percentage of p without evidence of disease progression after 6 months of erlotinib therapy and secondary endpoints were: PFS, OS, ORR and safety profile. Results: 49 p have been included in the study and data from 37 p are presented in this analysis. Baseline characteristics: median age 62 years (range 41–76); male 94.6%; caucasian 100%; smokers/never smokers (%) 97.3/2.7; ECOG PS 0/1/2 (%) 18.9/75.7/2.7; adenocarcinoma/squamous cell carcinoma/large cell carcinoma (%) 16.2/75.7/5.4; stage IIIA/IIIB (%) 16.2/83.8. Most common previous chemo-radiotherapy regimen is cisplatin/docetaxel/RT (83.8%). 27 p were evaluable for tumor response: CR 22.2%; PR 12.8%; SD 55.6%; PD 7.4%. Median TTP was 7.3 months (95% CI 5.8–16.9) and median OS was 18.7 months (95% CI 11.8-NA). Most common adverse events related to erlotinib were rash 30.6% (3 p gr. 3) and diarrhea 16.7%. Conclusions: Erlotinib as maintenance therapy is an active and well tolerated treatment after concurrent chemo- radiotherapy in p with stage III NSCLC. In spite of the majority of patients are caucasian, males, smokers with squamous cell carcinoma, maintenance with single agent erlotinib reached a promising median OS of 18.7 months. Updated data will be presented. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Casal
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - S. Vázquez
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - L. León
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - M. Lázaro
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - J. L. Fírvida
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - M. Amenedo
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - G. Alonso
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - L. Santomé
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| | - F. J. Afonso
- Complejo Hospitalario Universitario de Vigo, Hospital do Meixoeiro, Vigo, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; C.H. Universitario de Vigo, Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Complejo Hospitalario Arquitecto Marcide, Ferrol
| |
Collapse
|
6
|
Rubio JC, Vázquez S, Vázquez F, Amenedo M, Fírvida JL, Mel JR, Huidobro G, Alvarez E, Lázaro M, Alonso G, Fernández I. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol 2009; 64:379-84. [PMID: 19139896 DOI: 10.1007/s00280-008-0884-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2008] [Revised: 11/18/2008] [Accepted: 11/21/2008] [Indexed: 11/27/2022]
Abstract
PURPOSE To test efficacy and tolerability of non-platinum regimens for advanced non-small-cell lung cancer (NSCLC). METHODS Chemonaive patients with measurable stage IIIB/IV NSCLC treated with gemcitabine and cisplatin (GC), or gemcitabine and docetaxel (GD), maximumsix cycles in a phase IIB trial. RESULTS A total of 108 patients were randomized. Response rates (GC vs. GD, respectively): complete 3.6/2.0%, Partial 30.9/38.0%. Median Overall Survival (OS): 8.9 months in both groups (P = 0.53); and median time to progression (TTP): 6.2/5.5 months respectively (P = 0.61). Toxicities included (GC vs. GD, respectively): grade 3-4 neutropenia 49.1/41.2%; grade 3 thrombocytopenia 30.9/3.9%; grade 3 anemia 14.5/3.9%. Non-haematological toxicity was similar, except for nausea and vomiting, (16.3/2%); renal toxicity (3.7/0%) and hepatic toxicity (5.6/12.7%). CONCLUSIONS With a higher overall response rate and lower toxicity, GD is a good first treatment option for advanced NSCLC.
Collapse
Affiliation(s)
- Joaquín Casal Rubio
- Department of Medical Oncology, Hospital do Meixoeiro, C/Meixoeiro, s/n, 36200, Vigo (Pontevedra), Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Huidobro G, Vázquez S, Lázaro M, Mel JR, Casal J, Castellanos J, Vidal Y, Fírvida JL, Amenedo M. Docetaxel (D) and cisplatin (C) induction chemotherapy followed by bi-weekly D with concurrent thoracic radiotherapy for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Casal J, Vázquez S, Barón FJ, Fírvida JL, Amenedo M, Santomé L, Lázaro M, Alonso G. An open label non-randomized phase II trial of erlotinib following concurrent chemo-radiotherapy as maintenance therapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.18501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Vazquez-Estevez S, León L, Fírvida JL, Grande C, Vázquez F, Salgado M, Casal J, Barón FJ, Abal J, García J. Biweekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) 2: A phase II study of the Galician Lung Cancer Group. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Fírvida JL, Esquerdo G, Amenedo M, Salgado M, LLorca C, Pérez E, Cervera Grau J, Ramos M. Biweekly docetaxel and carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Finally results of a phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Fírvida JL, Vazquez S, Grande C, Leon L, Salgado M, Campos B, Lazaro M, López R, Pérez E, Casal J, Mel JR. Oral vinorelbine (NVBO) and gemcitabine (GEM) in elderly patients with advanced non-small-cell lung cancer (NSCLC): A phase II study conducted by the Galician Lung Cancer Group (GLCG). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Fírvida JL, Esquerdo G, Amenedo M, Salgado M, Llorca C, González A, Pérez E, Cervera JM, Ramos M. Biweekly docetaxel and carboplatin as first line chemotherapy in advanced non small cell lung cancer (NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17016 Background: Platinum therapy has been the backbone treatment in NSCLC. The concomitant use of platinum derivatives and taxanes has shown high antitumoral activity with moderate toxicity. To improve the therapeutic index of this combination, we performed a study with biweekly carboplatin and docetaxel. Primary objective was determination of objective response rate (ORR). Secondary objectives were time to progression, tolerability and overall survival. Methods: Patients histologically confirmed of non-small cell lung cancer, aged ≥ 18, ECOG PS 0–2, measurable lesion according RECIST criteria, adequate bone marrow, renal and hepatic function were included. Prior chemotherapy was not allowed. Patients received treatment with a combination of Docetaxel 50 mg/m2 and Carboplatin AUC-4 each 15 days for a maximum of 8 cycles. Results: Fifty patients were included between March 2004 and July 2005, 84% were male, median age was 63 years old (range 48–77), 78% had ECOG PS 0–1 and 64% of patients had stage IV. Histology was squamous cell carcinoma (54%) adenocarcinoma (36%) and large cell carcinoma (10%). A total 316 cycles were administrated (median 7, Range 1–12). Over 46 evaluable patients for response, one achieved CR, 13 PR, 21 SD and 11 PD, with an overall response rate of 30.5% (95% CI: 17.2–43.8). Median follow up of patients is 8.3 months, with a median TTP of 6.3 months and median overall survival of 11.1 months. Grade 3–4 toxicity per patient was: neutropenia (22.0%), asthenia (16.0%), anaemia (10.0%), thrombocytopenia (2%), mucositis (2%) and nauseas (2%). Conclusions: These results suggest that biweekly schedule of carboplatin / docetaxel is a safe and active regimen in first line advanced NSCLC patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. L. Fírvida
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - G. Esquerdo
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - M. Amenedo
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - M. Salgado
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - C. Llorca
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - A. González
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - E. Pérez
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - J. M. Cervera
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - M. Ramos
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| |
Collapse
|
13
|
Vázquez S, Huidobro G, Amenedo M, Fírvida JL, Lázaro M, Del Río L, Villanueva MJ, Álvarez E, Ramos M, Casal J. Biweekly docetaxel and vinorelbine as second-line treatment in advanced (stage IIIB+IV) non-small-cell lung cancer (NSCLC). A phase II study of the Galician Lung Cancer Group. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Vázquez
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - G. Huidobro
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - M. Amenedo
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - J. L. Fírvida
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - M. Lázaro
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - L. Del Río
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - M. J. Villanueva
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - E. Álvarez
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - M. Ramos
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| | - J. Casal
- H. Xeral, Lugo, Spain; H. Meixoeiro, Vigo, Spain; C. Oncolóxico, A Coruña, Spain; C. Hospitalario, Ourense, Spain; H. Xeral-Cíes, Vigo, Spain; C. H. Univ, Santiago de Compostela, Spain
| |
Collapse
|
14
|
Amenedo M, Vázquez F, Lázaro M, Casal J, Mel JR, Antón LM, Fírvida JL, Grande C, Castellanos J, Balcells M. A phase II study of irinotecan (CPT-11) and carboplatin in patients with previously untreated small cell lung cancer (SCLC): Preliminary results. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Amenedo
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - F. Vázquez
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - M. Lázaro
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - J. Casal
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - J. R. Mel
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - L. M. Antón
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - J. L. Fírvida
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - C. Grande
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - J. Castellanos
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| | - M. Balcells
- Centro Oncológico de Galicia, La Coruña, Spain; Hospital Arquitecto Marcide, El Ferrol, Spain; Hospital Xeral-Cíes, Vigo, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral-Calde, Lugo, Spain; Hospital Juan Canalejo, La Coruña, Spain; Complexo Hospitalario, Ourense, Spain; Prasfarma / Almirall, Barcelona, Spain
| |
Collapse
|
15
|
León L, Cueva-Banuelos JF, Huidobro G, Fírvida JL, Amenedo M, Lázaro M, Romero C, Estévez SV, Barón FJ, Grande C, García Mata J, González A, Castellanos J, Gómez A, Caeiro M, Rodríguez MR, Casal J. Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group. Lung Cancer 2003; 40:215-20. [PMID: 12711124 DOI: 10.1016/s0169-5002(03)00030-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
PURPOSE To determine the effectiveness of a gemcitabine-cisplatin-vinorelbine combination in patients with stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients (n=46) with stage III NSCLC and naive of therapy were recruited into the trial to receive gemcitabine (G, 1000 mg/m(2)) on days 1 and 8, cisplatin (C, 100 mg/m(2)) on day 1 and vinorelbine (V, 25 mg/m(2)) on days 1 and 8 every 21 days for three cycles. RESULTS Two patients achieved complete response (CR) and 23 partial response (PR), overall response 52%. Subsequent radical surgery included nine patients of whom four were non-resectable and five were resected and with 1 CR. Radiotherapy was administered to 31 patients, and two achieved CR. The median time to progression and overall survival were 37 and 50 weeks, respectively. Grade 3-4 neutropenia and thrombocytopenia occurred in 35% of cycles, with two toxic deaths. Severe non-haematological toxicity was uncommon. CONCLUSIONS This GCV combination is effective in patients with stage III NSCLC, and with an acceptable toxicity.
Collapse
Affiliation(s)
- Luis León
- Galician Lung Cancer Group, Pontevedra, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Fírvida JL, Irigoyen A, Vázquez-Estévez S, Díz P, Constenla M, Casal-Rubio J, Valladares-Ayerbes M, Castellanos J, Rodríguez R, Balcells M. Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer 2001; 91:704-11. [PMID: 11241237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
BACKGROUND The objective of this multicenter, open-labeled, Phase II study performed in Spain was to assess the efficacy and safety of irinotecan (CPT-11) as first-line chemotherapy for patients suffering from advanced colorectal carcinoma (CRC). METHODS Patients with histologically proven CRC and at least one bidimensionally measurable lesion, ages 18-70 years, with a performance status < or = 2, normal analytical values, and no prior chemotherapy or only adjuvant chemotherapy completed before study entry were selected. The treatment schedule was CPT-11 350 mg/m(2) intravenously administered once every 3 weeks. Both tumor response and toxicity were assessed using the World Health Organization and National Cancer Institute common toxicity criteria. Changes in performance status, weight, and symptoms also were measured. RESULTS Sixty-five patients (44 chemotherapy-naïve patients and 21 patients who completed prior adjuvant treatment) were enrolled. Of these, 24.7% of patients responded to the treatment, and 41.5% of patients had stable disease. Patients who had not received prior adjuvant chemotherapy had a lower rate of progression on therapy (27.3%) compared with those who had received prior adjuvant chemotherapy (42.9%). The median survival was 19.9 months (range, 0.3-29.3 months). No significant differences were found in the median survival between chemotherapy-naïve patients and patients who had received previous chemotherapy. Grade 3-4 diarrhea and neutropenia were the most frequent severe toxic events, which were observed in 23.1% and 30.8% of patients and in 5.9% and 10.9% of the cycles, respectively. CONCLUSIONS The current antitumor efficacy results show that 350 mg/m(2) of CPT-11 administered every 3 weeks is an active and feasible first-line chemotherapy regimen for patients with CRC. Finally, the overall safety data confirmed that CPT-11 is a well tolerated treatment.
Collapse
Affiliation(s)
- J L Fírvida
- Complexo Hospitalario de Ourense, Ourense, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Parajó A, Fírvida JL, Otero E, García M, Montero M. [Isolated primary hyperaldosteronism caused by adrenocortical carcinoma]. ARCH ESP UROL 2000; 53:931-4. [PMID: 11213398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
OBJECTIVE To report a case of adrenocortical carcinoma and primary aldosteronism as the sole endocrine manifestation. METHODS/RESULTS A 39-year-old male with adrenocortical carcinoma and primary aldosteronism is presented. Following complete hormonal and radiological evaluation, right adrenalectomy and nephrectomy were performed (pT2pN0M0, stage II). Blood pressure, serum potassium and aldosterone levels returned to normal. The patient received adjuvant therapy with carboplatin and etoposide. After 15 months' disease-free interval, lung metastasis was diagnosed, without evidence of local recurrence until 5 months later, when hypertension and primary hyperaldosteronism reappeared. There were no other endocrine disorders. Treatment with spironolactone, 5-FU and adriamycin was instituted with no tumor response and the patient died 3 years later from complications of endobronchial metastasis. CONCLUSION Adrenocortical carcinoma with isolated primary hyperaldosteronism is uncommon and consequently there is no wide experience in regard to its diagnosis and treatment. Although randomized studies are not available, adjuvant therapy using other agents instead of mitotane (o,p-DDD), such as the combination of cisplatin and etoposide (VP-16), seems reasonable in the locally advanced stages. Mitotane may be useful when hypercortisolism is present, but its efficacy as an antitumor agent has been controversial.
Collapse
Affiliation(s)
- A Parajó
- Servicio de Cirugía, Hospital Santa María Nai, Orense, España
| | | | | | | | | |
Collapse
|
18
|
Fírvida JL, Viñolas N, Muñoz M, Grau JJ, Daniels M, Estapé A, Estapé J. Age: a critical factor in cancer management. A prospective comparative study of 400 patients. Age Ageing 1999; 28:103-5. [PMID: 10350404 DOI: 10.1093/ageing/28.2.103] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND older people are often excluded from cancer treatments solely on the grounds of age. AIMS to compare cancer treatment in older and younger patients. PATIENTS AND METHODS between June 1992 and September 1994, 400 cancer patients were included in this prospective comparative study. The factors compared between younger and older subjects were performance status, associated chronic diseases, delay in diagnosis, stage of disease and initial treatment. RESULTS 54 patients (25.5%) under 70 years of age were asymptomatic at the time of diagnosis, in comparison with 25 (12.5%) of the 200 older patients (P < 0.001). Associated chronic pathologies were more frequent in the older patients (55% vs 18.5%, P < 0.001). There were no statistical differences between both groups in diagnostic delay. Localized disease was found in 127 (63%) of the younger patients and in 109 (54%) of the older patients, the difference not being significant. The percentage of patients who underwent oncological treatment was higher in the younger than the older group (87.5% vs 56%, P < 0.001). The main cause of therapeutic exclusion in both groups was poor performance status; however, in the older group other variables--such as the presence of chronic disease and patients' or relatives' wishes and doctors' opinions--influenced the decision not to give specific treatment. CONCLUSIONS this study confirms that the clinical characteristics and treatment of aged people with cancer are different from those of younger patients. Nevertheless, there is considerable doubt about whether an arbitrary age limit should continue to be accepted as a discriminatory factor in some diagnostic and therapeutic procedures in cancer patients.
Collapse
Affiliation(s)
- J L Fírvida
- Servicio de Coordinación Oncológica, Hospital Clinic, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
19
|
Grau JJ, Cuchi A, Traserra J, Fírvida JL, Arias C, Blanch JL, Estapé J. Follow-up study in head and neck cancer: cure rate according to tumor location and stage. Oncology 1997; 54:38-42. [PMID: 8978591 DOI: 10.1159/000227659] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The purpose of this clinical study was to analyze a long-term follow-up of all the patients with head and neck cancer in our institution. Between 1973 and 1993, 1,355 consecutive cases of head and neck cancerwere diagnosed, treated and followed up regularly. All were subjected to a multidisciplinary approach, and followed up until death or for 10 years with no event of disease. The local relapse rate was 20% and the node-regional relapse rate 15%. Distant metastases were observed in 6% of the patients mainly arising from the nasopharynx (23%) followed by the hypopharynx (11%). The main organ involved was the lung (50%). Median follow-up of the group was 10 years (range 4 months to 15 years). Cancer cure was observed after 5 years in glottic and supraglottic laryngeal carcinoma, oral and nasopharyngeal cancer and after 2.5 years in patients with cancer of the oropharynx and hypopharynx. The highest cure rate was 80% in the glottis, followed by 70% in the supraglottic area, 45% in the mouth, 30% in the nasopharynx, 25% in the oropharynx, and 20% in the hypopharynx. A second primary tumor was observed in 7% of the patients and a third primary in 0.6% of the patients. Only in 7 patients, the second or third primary was seen after 5 years of follow-up. Curability should be observed after 5 years from definitive therapy of glottic, supraglottic, oral and nasopharyngeal and earlier in oropharyngeal and hypopharyngeal cancer. Further follow-up should be discontinued. Second and third neoplasias are the main problems after 5 years of follow-up but their incidence is low.
Collapse
Affiliation(s)
- J J Grau
- Department of Medical Oncology, Hospital Clinic, University of Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
We have studied the effect on ototoxicity of maintaining serum calcium concentration by calcium gluconate infusion in cancer patients receiving high-dose cisplatin in a randomized study in two groups: 11 patients received calcium gluconate, 4 mg kg-1 i.v. infusion during cisplatin therapy; 11 other patients without any calcium supplementation served as controls. All of them received the first course of chemotherapy, based on cisplatin, 120 mg m2 with a hydration schedule. An audiogram was performed in each patient just before cisplatin and repeated after 1 day and 3 weeks. Mean total calcium concentration in control patients before and after chemotherapy was 2.2 +/- 0.14 (95% confidence interval 1.9-2.5) and 2.0 +/- 0.13 (95% CI 1.7-2.24) mmol 1(-1) respectively (P = 0.0004) and for ionized calcium 1.22 +/- 0.52 (95% CI 0.21-2.23) and 1.11 +/- 0.07 (95% CI 0.97-1.25) mmol 1(-1) respectively (P = 0.0005). Serum magnesium levels were maintained or increased by magnesium supplementation. Although there was no change in serum total or ionized calcium, or serum magnesium in the calcium infusion group, no differences in hearing loss between the groups were observed. High-dose cisplatin chemotherapy for cancer patients induces an acute decrease of serum total calcium and serum ionized calcium and audiometric changes. Maintenance of calcium serum levels by calcium gluconate infusion did not protect against ototoxicity in those patients.
Collapse
Affiliation(s)
- J J Grau
- University of Barcelona, Hospital Clinic, Medical Oncology Department, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
21
|
Grau JJ, Cuchi A, Estapé J, Arias C, Mañé JM, Fírvida JL, Moreno F, Traserra J. Survival after chemotherapy with cisplatin and infusion of bleomycin prior to local-regional treatment in pyriform sinus cancer. Tumori 1996; 82:221-4. [PMID: 8693597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
AIMS AND BACKGROUND The purpose of this study was to retrospectively compare different approaches including neoadjuvant chemotherapy. METHODS Ninety-six consecutive patients with pyriform sinus squamous cell carcinoma with no distant metastases were entered. The first 48 patients were treated with surgery plus postoperative radiation therapy (50-60 Gy) over cervical lymphatics. The next 48 patients were treated by induction chemotherapy with two courses of cisplatin, 120 mg/m2 i.v. day one, plus bleomycin, 20 mg/m2/day for 5 consecutive days in 24-hr i.v. perfusion followed by definitive surgery and postoperative radiation therapy as in the first therapeutic group. RESULTS Definitive surgery was performed in 38 control vs 39 neoadjuvant patients. Complete response was observed in 9 (18.7%) and partial response in 32 (66.7%) of 48 chemotherapy-treated patients. Partial plus complete response was seen in 41 (85.4%) of the 48 patients. Comparison between controls versus chemotherapy-treated groups showed persistence of the disease in 10 vs 9 patients; local-regional relapses in 21 versus 14 patients; and distant metastases in 4 vs 2 patients. Median survival was 12 vs 40 months. Survival curves were statistically better in neoadjuvants than in controls (P < 0.025). CONCLUSIONS Multidisciplinary therapy slightly decreases the rate of local-regional relapses and distant metastases and should improve survival in this set of pyriform sinus cancer patients.
Collapse
Affiliation(s)
- J J Grau
- Department of Medical Oncology, Hospital Clinic, University of Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|